Vybrique is a drug owned by Ibsa Institut Biochimique Sa. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 16, 2033. Details of Vybrique's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11123287 | Orodispersible Films Having Quick Dissolution Times For Therapeutic And Food Use |
Dec, 2033
(7 years from now) | Active |
FDA has granted several exclusivities to Vybrique. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Vybrique, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Vybrique.
Exclusivity Information
Vybrique holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Vybrique's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 16, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Vybrique is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Vybrique's family patents as well as insights into
ongoing legal events
on those patents.
Vybrique's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vybrique's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 16, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vybrique Generic API suppliers:
Sildenafil Citrate is the generic name for the brand Vybrique. 35 different companies have already filed for the generic of Vybrique, with Hetero Labs Ltd V having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vybrique's generic
Alternative Brands for Vybrique
There are several other brand drugs using the same active ingredient (Sildenafil Citrate) as Vybrique. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sildenafil Citrate, Vybrique's active ingredient. Check the complete list of approved generic manufacturers for Vybrique
About Vybrique
Vybrique is a drug owned by Ibsa Institut Biochimique Sa. Vybrique uses Sildenafil Citrate as an active ingredient. Vybrique was launched by Ibsa in 2025.
Approval Date:
Vybrique was approved by FDA for market use on 16 December, 2025.
Active Ingredient:
Vybrique uses Sildenafil Citrate as the active ingredient. Check out other Drugs and Companies using Sildenafil Citrate ingredient
Dosage:
Vybrique is available in film form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 25MG BASE | FILM | Prescription | ORAL |
| EQ 75MG BASE | FILM | Prescription | ORAL |
| EQ 50MG BASE | FILM | Prescription | ORAL |
| EQ 100MG BASE | FILM | Prescription | ORAL |